ClinicalTrials.gg
RecruitingNCT05485376PACCSUpdated Nov 17, 2026

Pulmonary Artery Catheter in Cardiogenic Shock Trial

An interventional study of Pulmonary Artery Catheter in Cardiogenic Shock and Heart Failure, sponsored by Tufts Medical Center. Recruiting at 1 site in United States. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Tufts Medical Center · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2022; still recruiting 4 years 2 months later.
Updated Nov 17, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 50 studies in Shock, Cardiogenic with a site in United States — 19 open to participants now, 23 under way, none of them phase 3. Shock, Cardiogenic · United States.

Planned enrollment
2nd of 25
400 · median 30
Started
2022
with 6 others
No phase
13 of 50
5 open now
Primary completion
2027-09
later than 9 of 22 live
Registered
28th of 50
by date
Lead sponsor
3 of 50
Tufts Medical Center

Among the 50 studies in Shock, Cardiogenic with a site in United States, this one is the 2nd largest by planned enrollment of the 25 interventional ones that give a count, is one of 7 that started in 2022, is one of 13 with no phase, reaches primary completion later than 9 of the 22 other live ones, and was the 28th registered.

Shock, Cardiogenic

297 studies on the registry are indexed under Shock, Cardiogenic; 134 are open to participants now.

Browse Shock, Cardiogenic studies →

Open to participants now

19 of the 50 studies in Shock, Cardiogenic with a site in United States are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 101 Shock, Cardiogenic studies recruiting now, 70 (69%) set no upper age limit and 9 (9%) stop at 75 or younger; 11 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies in Shock, Cardiogenic with a site in United States, or all of them as a file.
02

Study summary

The primary objective of the PACCS trial is to assess if early invasive hemodynamic assessment and ongoing management with a PAC in patients with cardiogenic shock due to acutely decompensated heart failure (AHDF-CS) is associated with lower in-hospital mortality risk compared to the current standard of care with no or delayed PAC assessment.

Read the detailed description

The PACCS trial is a multicenter, randomized, parallel group, adaptive trial that will test the hypothesis that early invasive hemodynamic assessment (within 6 hours of randomization) and ongoing management with a PAC decreases in-hospital mortality compared to clinical management with delayed (beyond 48 hours after randomization) or no PAC-guided assessment among patients with cardiogenic shock due to acutely decompensated heart failure (AHDF-CS). The trial uses an adaptive sample size re-estimation design. An interim analysis will be performed when the primary endpoint is available for 200 participants and may lead to an increase in the target sample size (minimum sample size 400, maximum sample size 800).

03

Conditions studied

  • Cardiogenic Shock
  • Heart Failure

Keywords

  • Pulmonary Artery Catheter
04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 years and ≤90 years
  2. Clinical heart failure presentation and left ventricular function as follows: Either 2A or 2B must be present A. Subject has de novo acute decompensated heart failure and shock with an ≤40% OR B. Subject has acute on chronic heart failure with a documented history of a LVEF ≤40% within 6 months of admission and a current LVEF ≤40% within 24 hours of screening during the current hospitalization.

    NOTE: The LVEF must be quantitatively measured as ≤ 40% by an echocardiogram within 24 hours of screening. If multiple echocardiograms have been performed within 24 hours, the most recent test must be used to qualify the patient.

  3. Cardiogenic Shock (CS) defined by a lactate level ≥ 2.1 mmol/L and any 2 of the following parameters within 24 hours of screening:

    1. SBP \<90 mmHg for more than 30 minutes from baseline SBP
    2. Requires the use of at least 1 vasopressor or inotrope
    3. Requires intra-aortic balloon pump (IABP) support
    4. Presence of congestion on exam: JVP elevated, pulmonary edema on CXR or exam, dyspnea at rest, orthopnea, bendopnea, or worsening peripheral or abdominal swelling
  4. Initial diagnosis of CS within 24 hours of screening at the enrolling site
  5. Patient or legally authorized representative provides

A HIPAA waiver for screening is requested to identify potential subjects. No recruitment materials will be given to potential subjects. No identifiable data will be retained for subjects that are determined to be ineligible

Exclusion criteria

Exclusion Criteria:

  1. Primary etiology of shock other than systolic left heart failure including but not limited to: acute myocardial infarction, sepsis, hypovolemia, hemorrhage, severe anemia, primary RV failure, pulmonary embolism, or tamponade.
  2. Patient has a durable ventricular assist device or temporary mechanical circulatory support (other than IABP) or PAC prior to enrollment
  3. Actively listed for cardiac transplantation (Status 7 patients are eligible for the trial)
  4. Patient transferred from another facility with a diagnosis of cardiogenic shock
  5. Any known co-morbidity other than heart failure with anticipated survival \< 6 months
  6. Pre-enrollment labs (any of the following): (INR) > 3, count \< 50k, \< 7
  7. or recurrent cardiac arrest (>1 episode requiring defibrillation or cardiopulmonary resuscitation) within 24 hours prior to screening
  8. DNR/ DNI status
  9. Pregnancy, child-birth within 6 months, or lactation
  10. Active infection documented by persistent fever (Temp > 38.4oC within 24 hours of screening) or confirmed bacteremia
  11. Implantation of PPM or ICD within past 3 months
  12. Mechanical complication of AMI (ie VSD, papillary muscle rupture, flail mitral regurgitation, free wall rupture)
  13. Anoxic brain injury
  14. On renal replacement therapy prior to enrollment
  15. Cardiac surgery within 3 months of current admission
  16. Severe aortic, pulmonic, tricuspid stenosis or acute structural mitral regurgitation or infective endocarditis
  17. History of cardiac amyloid
  18. Congenital heart disease excluding the presence of a bicuspid aortic valve
  19. Planned cardiac surgery during admission
  20. World Health Organization (WHO) Group I, III, IV, or V pulmonary hypertension
  21. Any known to PAC placement
  22. Participation in the active treatment or follow-up phase of another clinical study of an drug or device that has not reached its primary endpoint
  23. Any medical or psychiatric condition such as dementia, alcoholism, or substance abuse which may preclude or interfere with any of the study procedures, including follow-up
  24. Prior stroke with any permanent neurologic deficit or any prior intracranial hemorrhage or any prior subdural hematoma or known intracranial pathology pre-disposing to intracranial bleeding, such as an arteriovenous malformation or mass
  25. Subject has previously hospitalized for COVID-19 unless he/she has been discharged and asymptomatic for ≥4 weeks
  26. Subject is COVID-19 PCR/antigen positive within the prior 4 weeks
  27. Subject belongs to a vulnerable population [defined as individuals with mental disability, persons in nursing homes, impoverished persons, homeless persons, nomads, refugees and those permanently incapable of giving informed consent; vulnerable populations also may include members of a group with a hierarchical structure such as university students, subordinate hospital and laboratory personnel, members of the armed forces and persons kept in detention]
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
400 participants (estimated)

Study arms

  • Experimental
    Early Pulmonary Artery Catheter

    If you are in the experimental group a PAC will be placed within 6 hours of randomization and within 24 hours of presentation with ADHF-CS.

    Device: Pulmonary Artery Catheter

  • No intervention
    No or delayed Pulmonary Artery Catheter

    If you are in the control group, a PAC will not be placed during hospitalization or may be placed 48 hours after randomization into the study. Placement of a PAC within 48 hours is only permitted for emergencies.

Interventions

  • DevicePulmonary Artery Catheter

    The pulmonary artery catheter (PAC) is a diagnostic instrument that enables continuous hemodynamic monitoring of cardiac filling pressures, cardiac output, and pulmonary pressures.

06

What researchers measure

Primary outcomes

  1. Number of participants who die in the hospital

    Time frame: Length of stay in hospital, an average of 30 days

Secondary outcomes

  1. Number of Participants with in-hospital Cardiac Arrest

    Time frame: Length of stay in hospital, an average of 30 days

  2. Number of Participants that require Mechanical Ventilation

    Time frame: Length of stay in hospital, an average of 30 days

  3. Number of Participants that require Renal Replacement Therapy

    Time frame: Within 96 hours of randomization

  4. Length of stay in CCU or ICU

    Time frame: Length of stay in hospital, an average of 30 days

  5. Occurrence of heart transplantation and durable LVAD implantation

    Time frame: Length of stay in hospital, an average of 30 days

  6. Death

    Time frame: 30 days and 6 months after discharge

  7. Heart failure hospitalizations/emergency room visits

    Time frame: 30 days and 6 months after discharge

  8. Admission to an outpatient IV diuretic center

    Time frame: 30 days and 6 months after discharge.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Filipescu R, Collins SP, Radu RI, Ben Gal T, Antohi L, Abdelhamid M, Geavlete O, Pana M, Farmakis D, Matei DC, Savarese G, Margineanu C, Polovina M, Miro O, Guz D, Palazzuoli A, Masip J, Adamo M, Ambrosy AP, Chioncel O. Therapeutic Advances in the Management of Cardiogenic Shock. Am J Ther. 2026 Mar-Apr 01;33(2):e132-e145. doi: 10.1097/MJT.0000000000002025. Epub 2026 Jan 15. PubMed 41543923 ↗
  • Jung RG, Stotts C, Gupta A, Prosperi-Porta G, Dhaliwal S, Motazedian P, Abdel-Razek O, Di Santo P, Parlow S, Belley-Cote E, Tran A, van Diepen S, Harel-Sterling L, Goyal V, Lepage-Ratte MF, Mathew R, Jentzer JC, Price S, Naidu SS, Basir MB, Kapur NK, Thiele H, Ramirez FD, Wells G, Rochwerg B, Fernando SM, Hibbert B. Prognostic Factors Associated with Mortality in Cardiogenic Shock - A Systematic Review and Meta-Analysis. NEJM Evid. 2024 Nov;3(11):EVIDoa2300323. doi: 10.1056/EVIDoa2300323. Epub 2024 Oct 22. PubMed 39437131 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2022 (actual). Primary completion is estimated for Sep 2027, 60 months after the start.

Of 48 non-industry interventional studies with no phase under Shock, Cardiogenic, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 55. This study's planned 60 months is above that.

Counting every sponsor, half of 52 studies reached it within 39 months; a quarter within 24 and three quarters within 55.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 17, 2026: primary completion Sep 2026 → Sep 2027 and completion Sep 2026 → Sep 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 17, 2022
First posted
Aug 3, 2022
StartActual
Aug 23, 2022
Primary completionEst.
Sep 1, 2027was Sep 2026
CompletionEst.
Sep 1, 2028was Sep 2026
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 1, 2026→Sep 1, 2027
Nov 17, 2026
Study completion
Sep 1, 2026→Sep 1, 2028
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Primary completion Sep 1, 2026→Sep 1, 2027
    Study completion Sep 1, 2026→Sep 1, 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05485376
Responsible party
Sponsor
First posted
Aug 3, 2022
Start date
Aug 23, 2022
Primary completion
Sep 1, 2027 (estimated)
Completion
Sep 1, 2028 (estimated)
Last update
Nov 17, 2026

Study contacts

Karol Walec
Contact
kwalec@tuftsmedicalcenter.org
617-636-4907
Vanessa Palomo
Contact
vpalomo@tuftsmedicalcenter.org
Navin K Kapur, MD
principal investigator · nkapur@tuftsmedicalcenter.org

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion